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Tinnitus, the phantom perception of sound, in the absence of 
a corresponding external sound source, is a highly prevalent 
and debilitating disorder.1 At present, between 10 and 20% of 
the world population experiences tinnitus,2 prevalence rates 
are increasing, and it augments with age.3 In addition, severe 
tinnitus, which afflicts 1–2% of the general population, can 
lead to anxiety, depression, cognitive dysfunction, insomnia, 
and to an important decrease in the quality of life. Thus, it 
has recently been suggested that it should be considered a 
global burden.4
A wide variety of approaches have been used in an 
attempt to delineate the neural correlates of tinnitus. These 
range from experiments in animal models to brain imaging, 
magnetoencephalography, and electrophysiology studies in 
humans. Although early studies considered it a pathology of 
cochlear origin, recent data suggest that tinnitus is a central 
nervous system (CNS) disorder and that in can be consid-
ered an emergent property of multiple, parallel, dynamically 
changing, and partially overlapping subnetworks.5 However, 
the exact mechanisms underlying this phantom perception 
are still unknown. In fact, when compared with other CNS 
pathologies for which perturbations in different neurotrans-
mitter systems or in ion channel activity have been associ-
ated,6–8 no clear target systems have been associated with 
tinnitus. Moreover, although a wide variety of compounds 
are used off-label to treat tinnitus patients, there is still no 
US Food and Drug Administration or European Medicines 
Agency approved drug on the market.9 Thus, further com-
prehensive approaches are needed to better understand this 
pathology.
In the last decade, all aspects of life sciences have wit-
nessed a fabulous explosion of available data which are 
deposited in databanks. This is true for drug and drug–target 
information. Network approaches have proven useful for 
organizing these high-dimensional biological data sets and 
extracting meaningful information,10 and the term network 
pharmacology or systems pharmacology has been coined.11 
Interestingly, a high-throughput electronic-biology approach 
based on in silico data mining of existing databases and 
integration of this information has been proposed for drug 
discovery and repurposing.12,13 Networks have been applied 
to the analysis of the topological and global properties of 
drug–protein interactions, demonstrating that most CNS 
drugs are promiscuous, aiming at more than one target.14,15 
Moreover, new molecular targets for old drugs have been 
predicted and in some cases, they have been validated 
experimentally.14,16
A variety of ways whereby network approaches can be used 
toward understanding tinnitus have been proposed recently.17 
In particular, the high-throughput analysis of drug side-effect 
information to predict targets leading to this pathology might 
result informative. The strategy is based on the notion that 
treatment of patients with drugs is an in vivo chemical pertur-
bation experiment in a complex organism,18 that similar side 
effects of unrelated drugs can be caused by their common 
off-targets,18 and that the analysis of the mutual interactions 
of chemicals and proteins by means of network analysis 
enables a better understanding of the molecular mechanisms 
of disease, drug action, and associated adverse effects.14 In 
the present work, we built and analyzed a drug–target net-
work based on compounds that have been documented to 
elicit tinnitus as side effect, in order to explore the tinnitus 
target space. Making use of this network pharmacology side-
effect approach, we describe novel emergent protein targets 
predicted to be associated with tinnitus pathology. The pres-
ent work further aids the understanding of the underlying 
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mechanisms leading to tinnitus and opens the path for the 
development of new pharmacotherapies.
RESUlTS
Tinnitus drug–target network
The Side Effect Resource Database (SIDER 2; http://sideef-
fects.embl.de) reports a total of 4,192 side effects and 996 
drugs;19 of these, 275 with side effect tinnitus and synonyms 
occurring on labels, such as “ringing in ears,” “ringing in the 
ear,” and “ear noise” (Supplementary Table S1). We retrieved 
all targets for drugs that produce tinnitus as side effect from 
our reference database (created as described in Methods 
based on DrugBank, http://www.drugbank.ca/ and Psycho-
active Drug Screening Program (PDSP) Ki, http://pdsp.med.
unc.edu/pdsp.php) and generated a bipartite graph of 1,313 
drug–protein interactions in which a drug and a protein are 
connected to each other by an edge or link if the protein 
is a reported target of the drug, resulting in a drug–target 
network. To analyze the drug space of tinnitus as side effect, 
target node sizes were minimized, and drug nodes were 
colored according to their Anatomical Therapeutic Chemical 
code, generating the Drug Network (Figure 1). Drug nodes 
were not weighted, e.g., all nodes were given equal size. If 
most drugs only targeted a single protein, the network would 
consist of isolated nodes with few or no edges between 
them. However, as previously reported, most drugs are 
promiscuous and bind to more than one target;14,15,20 there-
fore, the network was highly connected. There was a main 
giant component (the largest connected component) which 
comprised 180 drugs. Within this giant component, 47% of 
drugs were nervous system acting (red nodes in Figure 1 
and Supplementary Table S2) and were mainly clustered, 
with an average number of neighbors of 10.6 compared 
with 4.3 (including the nervous system drugs) for the whole 
network, indicating an important number of shared targets. 
Moreover, 90% of nervous system compounds were found 
within the giant component, including antidepressants, anti-
psychotics, and opioids. Cardiovascular system drugs were 
the second (20%) most highly represented group within 
the giant component (Supplementary Table S2), compris-
ing beta blockers, calcium channel blockers, angiotensin 
antagonists, and statins. An additional cluster of drugs was 
clearly identified within the giant component as a separate 
neighborhood with an average number of neighbors of 4.6. 
This mainly contained musculoskeletal first-level Anatomical 
Therapeutic Chemical code drugs (green nodes in Figure 1) 
with anti-inflammatory activity. There were several small, iso-
lated components. One component worth noting is the one 
composed of nine cardiovascular acting drugs (dark orange, 
upper right panel, Figure 1), which were all angiotensin-
converting enzyme (ACE) inhibitors.
To further analyze the target space of tinnitus as side 
effect, drug nodes were minimized, and targets were col-
ored according to their family group, giving rise to the Tar-
get Network (Figure 2). The network was not weighted, 
e.g., all target nodes were given equal size. A total of 339 
different targets were found (Supplementary Tables S3 
and S4). As described for the Drug Network (Figure 1), a 
main giant component was observed, which contained 258 
targets. Within it, protein family members were mostly clus-
tered in different neighborhoods: cholinergic nicotinic recep-
tor subunits (CHRN), type A γ-aminobutyric acid receptor 
subunits (GABR), voltage-gated sodium channel subunits 
(SCN), voltage-gated calcium channel subunits (CACN), 
voltage-gated potassium channels (KCN), glutamate recep-
tors (GRI), and cyclooxigenase (COX) 1 and 2. An important 
neighborhood of highly clustered nodes from different pro-
tein families, derived from the promiscuity of nervous system 
acting drugs,20 included monoaminergic receptors (histamin-
ergic, HRH; adrenergic, ADRA; serotonergic, 5HT; and dopa-
minergic, DRD), cholinergic muscarinic receptors (CHRM), 
and monoaminergic transporters (SLC6). There were several 
small, isolated components, including the one composed 
of the ACEs. Although not shown in Figure 2, nodes in 
the Target Network had different degrees, e.g., number of 
links to different drugs. Supplementary Figure S1 shows 
the degree of the most targeted proteins and the total of 
hits for each one in the reference database. Some targets, 
like 5HT2A and HRH1, had the highest degree (33 and 25, 
respectively). However, they were also highly represented in 
the database (69 and 67, respectively). On the other hand, 
some targets like ACE had a low degree (9), but this was 
similar to the total number of hits in the reference database 
(10). Therefore, the degree of targets did not result in a good 
index for how significant any given target was in the network.
Emergent significant targets within the tinnitus network 
were identified as described in Methods, calculating an 
enrichment factor which identified targets that were more 
common than expected by chance and significant by χ2, 
corrected by false-discovery rate for multiple comparisons 
(Figure 3 and Supplementary Table S5). These were COX2 
(enrichment factor (EF): 2.39, q = 1 × 10−20), COX1 (EF: 2.26, 
q = 1 × 10−20), ACE (EF: 2.77, q = 0.006), 5HT1A (EF: 1.69, q 
= 0.03), SCN5A (EF: 2.05, q = 0.03), and SLC6A4 (EF: 1.66, 
q = 0.04). Targets belonged to four different neighborhoods 
(Figure 4): ACE, COX1/COX2, SCN5A, and the nervous 
system acting drug cluster mainly composed of aminergic 
receptors which contained 5HT1A and SLC6A4. Thus, ACE 
formed a completely isolated component. COX1 and COX2 
shared 25 of the 25 and 27 drugs that targeted COX1 and 
COX2, respectively. They shared no drugs with 5HT1A, 
SLC6A4, or SCN5A. 5HT1A and SLC6A4 shared 16 of the 
28 and 27 that targeted 5HT1A and SLC6A4 and shared no 
drugs with SCN5A.
Hearing impaired and hyperacusis drug–target networks
Tinnitus is very often accompanied by hearing impairment 
and/or hyperacusis.21,22 To differentiate between tinnitus, 
hearing impairment, and hyperacusis, we analyzed the drug 
and target space of “hearing impaired” and “hyperacusis” as 
side effect. For this purpose, we retrieved all drugs that pro-
duce these side effects from SIDER, 102 and 36, respectively 
(Supplementary Table S1). We obtained all drug targets 
from our reference database and generated bipartite graphs 
of drug–protein interactions. Target networks are shown in 
Supplementary Figures S2 and S3. Drug node sizes were 
minimized, and target nodes were colored according to fam-
ily members.
www.nature.com/psp
Tinnitus Side-Effect Network Analysis
Elgoyhen et al.
3
The hearing impaired Target Network contained 186 tar-
gets, 96 of them within the biggest component of the network. 
This contained SCN, voltage-gated potassium channels, 
cholinergic nicotinic receptor subunits, glutamate receptors, 
COX, and a clustered neighborhood which included mono-
aminergic receptors (HRH, adrenergic, 5HT, and dopaminer-
gic), cholinergic muscarinic receptors, and SLC6. Emergent 
hearing impaired targets are shown in Figure 5a. Worth not-
ing are COX2 (EF: 5.72, q = 1 × 10−20) and COX1 (EF: 5.73, 
1 × 10−20), emergent shared targets with tinnitus. The hyper-
acusis Target Network only contained 69 targets, 54 of them 
in a clustered neighborhood which included monoaminergic 
receptors (HRH, adrenergic, 5HT, and dopaminergic), cholin-
ergic muscarinic receptors, and SLC6. Emergent hyperacusis 
targets are shown in Figure 5b. Worth noting are SLC6A4 
(EF: 3.46, q = 0.00008), SCN5A (EF: 3.75, q = 0.004), and 
5HT1A (EF: 2.16, q = 0.05), emergent shared targets with 
tinnitus.
Figure 6 shows an integrated drug–target network for tin-
nitus, hearing impairment, and hyperacusis. Only emergent 
significant targets for each side effect are included and color 
coded. Shared targets between side effects have a different 
color, and drug–target links follow the same color code. For 
example, in purple, emergent targets that are only significant 
(and drugs that are only present) in the tinnitus drug–target 
network are shown. Thus, ACE is only significant for tinni-
tus, and ACE inhibitors only present in the tinnitus network. 
Tinnitus shares with hearing impairment COX1 and COX2 
Figure 1 Tinnitus drug network. A drug–target network was generated with Cytoscape 3.0, by retrieving all drugs that produce tinnitus as side 
effect from SIDER and their targets from DrugBank and PDSP Ki. An edge was placed between a drug node and a target node if the protein 
is a target of that drug in the reference database. Target nodes were minimized to visualize the tinnitus drug space. Drugs were color coded 
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and with hyperacusis, SLC6A4, 5HT1A, and SCN5A. Finally, 
hearing impairment and hyperacusis shared no emergent 
targets and drugs.
Depression as side effect
An increasing body of evidence suggests that tinnitus is 
not restricted to the characteristic “ringing in the ears” but 
instead encompasses a wide range of symptoms with emo-
tional components, such as depression.23 A priori, one could 
propose that depressed people refer more to “ringing in the 
ears,” because it is more bothersome for them and there-
fore they are more aware of it. To control for this potential 
confounder, we searched for an overlap of emergent targets 
between tinnitus and depression as side effect. Only 30 drugs 
are reported to produce side effect depression in SIDER 2 
(Supplementary Table S1), which are linked to 80 different 
targets (Supplementary Figure S4). Figure 5c shows the 
significant emergent targets in the depression network. None 
were significant in the tinnitus network.
DIScUSSION
Disorders of the CNS are complex disease states. They 
are a major challenge for clinical medicine and drug dis-
covery. Pathology is the result of multiple factors, which 
include environmental, genetic, and epigenetic imbalance 
in excitatory or inhibitory neurotransmission and alteration 
in modulatory neurotransmitter pathways (e.g., dopami-
nergic, cholinergic, and serotonergic).6–8 Although etiology 
is often unknown, the link between pathology and specific 
neurotransmitter systems and/or protein targets has been 
reported in most cases. Thus, in its acute psychotic state, 
schizophrenia is associated with an increase in dopamine 
synthesis and release as well as in resting-state synaptic 
dopamine concentrations.8 Similarly, several lines of evi-
dence show a direct link between serotonin neurotransmis-
sion and depressive disorders.7 Moreover, approved drugs 
that target the dopaminergic and serotonergic system are 
used to treat schizophrenia and depression, respectively. 
A different scenario is observed in the case of tinnitus, 
for which no clear endophenotype nor neural substrate is 
known and for which there is no approved drug on the mar-
ket.9 By making use of a network pharmacology approach 
based on drugs that produce tinnitus as side effect, in this 
article, we predict protein targets that might be involved in 
the genesis of tinnitus.
The use of large-scale side-effect data analysis for mak-
ing valid predictions in pharmacology has been recently 
Figure 2 Tinnitus target network. Same as in Figure 1, but drug nodes were minimized to visualize the tinnitus target space. Targets were 
color coded according to protein family members.
Figure 3 Significant tinnitus targets. Enrichment factors and χ2 
values are shown. Underlined are significant targets after correction 
for multiple comparisons by false-discovery rate (FDR). Statistical 
values for all targets are shown in Supplementary Table S5.
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demonstrated. Thus, Campillos et al.18 have successfully 
explored side-effect information generated from the use of 
746 marketed drugs to infer their molecular activity and pre-
dict additional targets for many existing drugs often impli-
cated in different therapeutic categories, some of which 
were validated experimentally. In addition, Lounkine et al.24 
used a computational large-scale strategy to predict new 
molecular targets for known drugs, based on chemical simi-
larity and thereafter targets that explain their side effects. 
The fact that COX1 and COX2, which are the main targets 
of salicylate, were found as the most significant emer-
gent targets in our analysis is a further proof of principle 
of the validity of these network pharmacology side-effect 
approaches. Thus, salicylate ototoxicity has been reported 
since the early 1900s. High-dose salicylate induces altera-
tions in perceived sounds, temporary hearing loss, and tin-
nitus in humans and is used as an animal model to study 
tinnitus.25 Interestingly, in their large-scale prediction and 
testing of drug activity on side-effect targets, Lounkine et 
al.24 also found that COX1 and COX2 are significantly asso-
ciated with tinnitus. Furthermore, they also found SCN5A 
significantly linked to tinnitus. However, different from our 
present study, they describe the association of tinnitus with 
HRH1, but not with ACE, SLC6A4, and 5HTA1. Differences 
could derive from the different databases used: SIDER vs. 
World Drug Index from Thompson Reuters (not freely avail-
able) for side effects and DrugBank plus PDSP Ki vs. Drug-
Bank plus ChEMBL, Thompson Reuters Integrity, GeneGo 
Metabase, and GVKBio for targets, in this article and in the 
study by Lounkine et al.,24 respectively. Moreover, our pres-
ent analysis was only based on drug–target associations 
linked to tinnitus, hyperacusis, hearing impairment, and 
depression, whereas the latter analysis integrated drug–
target information for 1,685 unique adverse drug reac-
tion terms, which did not include hyperacusis and hearing 
impairment. For an extended body of literature supporting 
the involvement of salicylate and suggesting the participa-
tion of the serotonergic system and voltage-gated sodium 
channels in the genesis of tinnitus, see Supplementary 
Table S9.
The fact that COX1/COX2, SCN5A, SLC6A4/5HTA1, and 
ACE belong to different neighborhoods most likely indicates 
that the underlying tinnitus-generating mechanism differs 
between drugs that aim those targets. This is consistent with 
the notion that tinnitus can be triggered by different mecha-
nisms and that different tinnitus subtypes most likely exist.4 
These underlying mechanisms could be unrelated to the 
described therapeutically relevant pharmacological effect 
of the side-effect–generating drug. For example, inhibition 
of COX1 and COX2 might not be the cause that leads to 
tinnitus. Instead, both cochlear and CNS effects of salicy-
late have been described.25 High-dose salicylate inhibits 
the binding of chloride to the anion-binding site on pres-
tin, thereby suppressing outer hair cell electromotility and 
cochlear amplification,26 induces a reversible increase in 
amplitude of cortical responses evoked by tone bursts over 
Figure 4 Neighborhoods of significant tinnitus targets. Shown are drug neighborhoods corresponding to the significant tinnitus targets (COX1/
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a wide range of frequencies and intensities,27 and increases 
expression of c-fos, an activity-dependent protein, in the 
auditory cortex, as well as in several nonclassical auditory 
regions (e.g., amygdala) associated with stress, anxiety, and 
emotion.28
The observation that the voltage-gated sodium channel 
SCN5A was significantly increased above a random obser-
vation supports the proposal that tinnitus might result from 
an imbalance in excitability anywhere along the auditory 
pathway.29 Moreover, the fact that SCN5 are sensitive to 
lidocaine30 and that the effects of lidocaine as a tinnitus sup-
pressor or enhancer have been well documented31 further 
highlight the validity of the present side-effect approach. 
Although SCN5, which encodes a tetrodotoxin-resistant 
sodium channel, is mainly a heart voltage-gated sodium 
channel subunit, expression of a variant in the brain has been 
described. SCN5 transcripts have been localized in limbic 
structures of rat and human brain,32 and the encoded protein 
has been found in various mouse brain regions including the 
cerebral cortex, thalamus, hypothalamus, and brain stem,33 
areas that are implicated in tinnitus-related brain subnet-
works.5 In addition, tetrodotoxin-resistant Na+ currents have 
been detected in neurons from the neocortex, hippocampus, 
and striatum.34,35
Because 5HTA1 and SLC6A4 belong to the same neigh-
borhood (Figures 2 and 4), it is difficult to determine if either 
one of the two targets or both are necessary as tinnitus trig-
gers. SLC6A4 encodes the serotonin transporter, which 
reuptakes the neurotransmitter serotonin from synaptic 
spaces into presynaptic neurons, and it is the main target of 
serotonin reuptake inhibitors which increase the concentra-
tion of serotonin at the biophase.20 Because only the 5HTA1 
receptor was significant, the effect of serotonin as a tinni-
tus trigger seems not to be widespread acting on several 
serotonin receptor subtypes. Therefore, the significance of 
SLC6A4 might result from an increase in serotonin concen-
tration acting on 5HTA1 receptors. According to DrugBank 
and PDSP Ki, drugs that targeted 5HTA1 receptors are ago-
nists (e.g., zolmitriptan, naratriptan, sumatriptan, pergolide, 
ropirinole, and rotigotine), partial agonists (e.g., buspirone 
and trazodone), and antagonists (e.g., quetiapine, dox-
epine, nortryptiline, nefazodone, and olanzapine). Thus, it is 
difficult to conclude which pharmacological effect results in 
the onset of tinnitus. However, one could propose that per-
turbation of serotonin neurotransmission is linked to tinni-
tus. Although serotonergic descending fibers to the cochlea 
have been documented,36 no clear effect of serotonin has 
been described at the auditory periphery. On the contrary, 
several CNS serotonergic-related effects have been docu-
mented. In particular, the thalamic reticular nucleus and 
the dorsal thalamus are innervated by serotonergic axons 
from the dorsal raphe nucleus, the nucleus accumbens, 
and other paralimbic regions.37 By exciting GABAergic neu-
rons of the thalamic reticular nucleus, these serotonergic 
projections inhibit sensory thalamic relay cells.38 Recently, 
the perturbation of a nucleus accumbens–thalamic reticu-
lar nucleus serotonergic “noise-cancellation system” has 
been proposed as the origin of the perception of persistent 
unpleasant noises, including phantom sensations such as 
tinnitus.39
The finding of ACE as a significant target is surprising, 
and to the best of our knowledge, the first time described 
to be associated with tinnitus. The classic renin–angiotensin 
system is a peripheral hormone system designed to medi-
ate cardiovascular and body water regulation, with angio-
tensin II as its major effector.40 One could propose that 
ACE-related alterations of cardiovascular and body water 
regulation might cause pulsatile or nonpulsatile tinnitus via 
alterations of cerebral blood flow and related flow noises. 
Alternatively, ACE-targeting drugs might induce tinnitus by a 
direct impact on brain activity via the brain renin–angiotensin 
system. A potential role of this system has been suggested 
Figure 5 Significant side effect targets. Enrichment factors and χ2 
values are shown for (a) hearing impaired, (b) hyperacusis, and 
(c) depression. Underlined are significant targets after correction 
for multiple comparisons by false-discovery rate (FDR). Statistical 
values for all targets are shown in Supplementary Tables S6–S8.
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for stress regulation and in pathologies such as depression 
and memory-related disorders.40 The angiotensin II recep-
tor (AT1 subtype) is present in the auditory system includ-
ing the cochlear nucleus and superior olivary nuclei,41 and 
the cochlear nucleus has been considered an important 
anatomical and physiological area in the development of tin-
nitus.42 In addition, a potential role of the brain renin–angio-
tensin system has been suggested in auditory attention.43 
Thus, this system might participate in sound and auditory 
attention and affective brain circuits related to tinnitus.
The fact that tinnitus shared targets with hearing impair-
ment and hyperacusis reflects the observation that it is 
often associated with these symptoms.21,22 Thus, COX1 and 
COX2 were shared targets between tinnitus and hearing 
impairment, which is consistent with the finding that salicy-
late leads not only to tinnitus but also to temporary hearing 
loss.25 On the other hand, 5HTA1 and SLC6A4 were shared 
targets between tinnitus and hyperacusis. An increased 
central nonlinear gain has been posited as the origin of both 
hyperacusis and tinnitus,44,45 which could result from a dys-
function of central serotonergic neurotransmission.46 Thus, 
the finding of 5HTA1 and SLC6A4 in the hyperacusis/tinni-
tus network but not in the hearing impaired/tinnitus network 
might support a serotonergic mechanism underlying a cen-
tral gain origin of tinnitus and hyperacusis, in the absence of 
overt deafferentation due to hearing loss. This is consistent 
with the observation that in some tinnitus patients, auditory 
sensitivity is enhanced even in the presence of a normal 
audiogram.45,47,48 The observation that hearing impairment 
and hyperacusis shared no common targets is surprising, 
since hyperacusis is sometimes accompanied with hear-
ing loss.22 However, it is possible that patients often report 
hyperacusis as a side effect due to the high discomfort it 
produces, whereas hearing impairment is not reported 
unless it is very profound.
In conclusion, the network integration of targets based on 
drugs that produce tinnitus as side effect indicates that sev-
eral distinct mechanisms are involved in the generation of 
tinnitus. Whereas ACE inhibitors cause tinnitus without hear-
ing loss or hyperacusis, many drugs that target COX1/COX2 
result in tinnitus with hearing loss, whereas drugs that target 
SCN5A or SLC6A4/5HTA1 generate tinnitus with associated 
hyperacusis. These results have important pathophysiologi-
cal implications and can further aid in dissecting the under-
lying neuronal correlates of sound phantom perception and 
associated disorders. In addition, the present study provides 
important clues concerning targets that can be investigated 
toward the further development of drugs to treat this enig-
matic condition of high prevalence.
METHODS
Reference database. A drug–target reference database was 
built with drugs and targets derived from DrugBank (http://
www.drugbank.ca/)49 and the National Institute of Mental 
Health PDSP Ki Database (http://pdsp.med.unc.edu/pdsp.
php). DrugBank combines comprehensive drug (e.g., chemi-
cal, pharmacological, and pharmaceutical) data with detailed 
drug–target (e.g., sequence, structure, and pathway) infor-
mation. PDSP Ki serves as a data warehouse for published 
and internally derived Ki, or affinity, values for a large num-
ber of drugs and drug candidates at an expanding number 
of G-protein–coupled receptors, ion channels, transporters, 
and enzymes. In some cases, the PDSP Ki database con-
tains entries for binding constants with complexes or groups 
of proteins that cannot be mapped to individual proteins (e.g., 
“calcium channel” and “sodium channel”) and were therefore 
not retrieved from this database. Both databases were down-
loaded as of September 2012 into excel files. Matlab (The 
MathWorks, http://www.mathworks.com) was used to obtain 
from DrugBank all drugs and their targets, and data were 
thereafter manually curated to only leave approved drugs 
that were also present in SIDER 2.19 PDSP was manually 
curated to retrieve approved drugs present in SIDER 2 and 
their targets (with binding affinities lower than 10 µmol/l). The 
reference database is composed of 781 drugs, 756 targets, 
and 3,728 drug–target interactions. Metabolizing enzymes, 
nonspecific protein binders, nonmammalian targets, DNA, 
and RNA were not included: e.g., targets with keywords multi-
drug resistance, cytochrome, ATP-binding cassette, glutathi-
one S-transferases, flavin-containing monooxygenase, and 
albumin.
Side-effect networks. Drugs producing side effect “tin-
nitus,” “hearing impaired,” “hyperacusis,” and “depression” 
(Supplementary Table S1) were downloaded from SIDER 
2.19 SIDER contains information on marketed medicines 
and their recorded adverse drug reactions extracted from 
public documents and package inserts. Frequency of 
adverse events was not taken into account. For each drug, 
all known targets were retrieved from the reference data-
base. Supplementary Tables S1, S3, and S4 show drug 
and target information for tinnitus, hearing impaired, hyper-
acusis, and depression. Based on drug–target associa-
tions, we generated bipartite networks for each side effect 
using Cytoscape 3.0 (ref. 50) to visualize the network. A 
link or edge was placed between a drug node and a tar-
get node if the protein is a reported target of that drug in 
the reference database. Nodes were denoted as circles 
and were not weighted. In the drug networks, target nodes 
were drawn at a smaller size to better view drug nodes. 
Drug nodes were classified according to the first level (the 
main category) of the Anatomical Therapeutic Chemical 
classification provided by the World Health Organization 
Centre for Drug Statistics Methodology (Supplementary 
Table S3). Each category was assigned a different color. 
For drugs with more than one classification, we assigned it 
“nervous system” when applicable. In the target networks, 
drug nodes were drawn at a smaller size to better visualize 
the target nodes. Target proteins were colored according to 
their protein family. Layouts for all networks were generated 
by a force-directed algorithm with default Cytoscape set-
tings, followed by a local manual rearrangement for visual 
clarity without modifying the overall layout of the network. 
Network parameters were obtained through the Cytoscape 
Network Analysis Plugin.
Statistical analysis. To assess the potential relevance of 
a specific target for a specific adverse event (i.e., tinnitus, 
www.nature.com/psp
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hearing loss, hyperacusis, and depression), we applied a χ2 
method previously introduced by Lounkine et al.24 (Supple-
mentary Tables S5–S8). To verify whether a specific target 
is expected above chance, we calculated an enrichment 




where EF is the enrichment factor of adverse drug reac-
tion for predicted targets, O the occurrence of a target, and 
E is the expected occurrence of a specific target. We calcu-
lated the expected occurrence of a specific target with the 
following formula:
E = A B
C
×
where A is the amount of drugs that have a specific tar-
get in the reference database, B is the total amount of drug–
target pairs that are linked to a side effect, and C is the total 
amount of drug–target pairs in the database.
For example, COX2 is targeted by 28 drugs that create 
tinnitus as an adverse event and by 36 drugs in the refer-
ence database. In total, there are 3,728 drug–target pairs in 
the reference database. A total of 1,211 drug–target pairs 
are linked to tinnitus. Accordingly, the pair tinnitus–COX2 
was enriched 2.39-fold above random, with a χ2 P value of 
5.5 × 10−9, which was still significant after correction for mul-
tiple comparisons by false-discovery rate (q = 1.0 × 10−20) 
(Supplementary Table S5). For calculations, drug–target 
pairs that were only represented once in the database were 
not considered. Moreover, after statistical analysis, only 
targets that were represented more than three times in the 
general database were taken into consideration.
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